Independent DirectorMember of Nomination and Remuneration Committees.
Mr Lankau is an experienced biopharmaceutical executive with over 30 years of experience in developing and commercializing pharmaceutical products. He is Principal of Lankau Consulting LLC, which provides advisory and consulting services to boards of directors and senior management of pharmaceutical and biotechnology companies, as well as venture capital and private equity firms. Mr Lankau was previously Executive Chairman of the Board for Nautilus Neurosciences, Inc., Chairman and CEO of Logical Therapeutics, Inc. and President, CEO and Director of Endo Pharmaceuticals. Prior to Endo, Mr Lankau was VP, Sales and Marketing for Alpharma, Inc. He began his pharmaceutical career with Rhone-Poulenc Rorer, Inc. (now Sanofi) in multiple commercial roles, and was most recently VP, Sales-US Pharmaceuticals. Mr Lankau also currently serves on the Board of Directors of ANI Pharmaceuticals, Inc., Board of Directors of Cipla Limited, and also on the Board of Advisors of Orchard Venture Partners, a life sciences venture capital firm.
CEO and Managing DirectorMember of Nomination Committee.
Dr Murdoch joined Phosphagenics as CEO in January 2015. He has more than 25 years experience as a leader within the global Healthcare, Pharmaceutical and Biotechnology Industry. He has held senior management and executive positions in Australia, USA and Europe, with responsibility for the strategy, development and commercialisation of products, product portfolios and the building and rebuilding of new and existing businesses. Highlights of his career include Senior Vice President at Shire Pharmaceuticals (one of the world’s leading Specialty Pharmaceutical companies), based in the USA and Switzerland, where he founded and grew both the Emerging Products Business and Haematology Business, and President and COO of Prana Biotechnology Limited based in Australia. Dr Murdoch has a BSc degree with honours from Monash University, a PhD in Clinical Pharmacology from the University of Melbourne, and additional postgraduate training in Health Economics from Monash University Business School.
Independent DirectorChairman of Nomination Committee.
Member of Remuneration, Audit and Risk Committees.
Dr Cauwenbergh started his career with Janssen Research Foundation in 1979 in Belgium. He moved to the USA in 1994 to take up the role of VP, Product Development for Johnson & Johnson. Subsequently, he was appointed Global VP of R&D for Johnson & Johnson Consumer companies worldwide. In 2001, Dr Cauwenbergh left Johnson & Johnson and founded Barrier Therapeutics, a company developing drugs to treat skin diseases. Barrier Therapeutics was acquired by Stiefel Laboratories in 2008. Dr Cauwenbergh is currently President and CEO of NASDAQ listed company RXi Pharmaceuticals (OTC: RXII). In this role, he has guided RXll through its initial public offering and helped it successfully prepare and submit its first US FDA Investigational New Drug Application.
Chairman and Independent DirectorChairman of Remuneration Committee.
Member of Nomination, Audit and Risk Committees.
Dr Collier is currently the CEO of ASX listed company Invion Ltd, and has more than 20 years’ experience spanning operational, clinical and scientific aspects of pharmaceutical research, development and commercialisation. He has executed multiple commercial transactions and has successfully taken a drug from discovery through to regulatory approval. Dr Collier steered ChemGenex Pharmaceuticals from a research-based company with a market capitalisation of $10M to a company that completed clinical trials and submitted regulatory dossiers to the FDA and EMA. In 2011 ChemGenex was sold to Cephalon for $230M. During Dr Collier’s distinguished academic career, before entering the commercial world, he published over 150 peer reviewed articles, as well as having senior authorship on 33 patents. Dr Collier was the inaugural Alfred Deakin Professor at Deakin University and also held positions at the University of Melbourne, Monash University and the University of Toronto. In 2010 Dr Collier was awarded the Roche Award of Excellence for his contribution to the biotechnology industry.
Non-Independent DirectorMr Segal joined the Board in May 2016. He was Investor Relations Manager at Phosphagenics from 2011 to 2015. He worked in stockbroking for over 30 years, including setting up, raising capital for and running Trent Securities which was absorbed into Shaw Stockbroking in 1992. Mr Segal has been a shareholder with Phosphagenics since 1999 when it was known as Vital Capital and has a close rapport with many shareholders whom he engaged with in his role as Investor Relations Manager or as an investment adviser at Shaw Stockbroking. He has a law/commerce degree from Melbourne University and is a Graduate of the Australian Institute of Company Directors.